VentriPoint Diagnostics Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA92281P2008
CAD
0.09
0 (-5.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About VentriPoint Diagnostics Ltd. stock-summary
stock-summary
VentriPoint Diagnostics Ltd.
Pharmaceuticals & Biotechnology
Ventripoint Diagnostics Ltd., formerly Luca Capital Inc., is a medical device company. The Company is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. By using images produced from existing medical imaging systems, the Ventripoint Medical System (VMS) generates accurate heart volumetric measurements and a three-dimensional (3D) model in a rapid and inexpensive manner. The Company's solution produces critical heart information by processing standard information received from existing medical imaging equipment with its methods incorporating Knowledge Based Reconstruction (KBR) algorithms and cardiac databases (catalogues). Its technology platform is applicable to all heart diseases. The Company has developed prototype analytical software package to be used with 4D echocardiograms (VMS-4DE) and one to be used with magnetic resonance imaging (MRI) images (VMS-CMR). It also focuses on developing VMS-Plus and the VMS-Nano.
Company Coordinates stock-summary
Company Details
2 Sheppard Ave E , NORTH YORK ON : M2N 5Y7
stock-summary
Tel: 1 416 8484156
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. George Adams
Chief Executive Officer, Director
Alan Rabinowitz
Director
Dr. Donald Segal
Director
Mr. David Willis
Director
Mr. Danny Dalla-Longa
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 17 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.43

stock-summary
Return on Equity

112.65%

stock-summary
Price to Book

-4.22